Adc Therapeutics Sa (ADCT)

$1.23 -0.04 (-3.15%)
Market Cap 160.26M
Revenue (ttm) 81.36M
Net Income (ttm) -142.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -175.30%
Debt to Equity Ratio -0.53
Volume 332,220
Avg Vol 2,037,344
Day's Range N/A - N/A
Shares Out 127.19M
Stochastic %K 24%
Beta 1.87
Analysts Sell
Price Target $5.00

Company Profile

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemi...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 41 21 653 02 00
Address:
BiopOle, Route de la Corniche 3B, Epalinges, Switzerland
Flying_Trader2
Flying_Trader2 Jul. 20 at 12:08 AM
$ADCT that pullback from 1.45 was disappointing. But we have a couple of important catalysts coming soon so this is either going to 4+ or pennies by year end.
0 · Reply
Spartrap
Spartrap Jul. 19 at 11:47 AM
$ADCT short interest is stable
0 · Reply
XQuise
XQuise Jul. 17 at 2:11 PM
$ADCT 🧠👈🏻🫶🏻
1 · Reply
StockConsultant
StockConsultant Jul. 17 at 1:14 PM
$ADCT Adc Therapeutics stock, watch for an upside gap breakout at https://stockconsultant.com/?ADCT Breakout trade WATCH for possible breakout above 1.37 Target: 1.68, 24.4% Stop: 1.23 Loss: 8.9% P/L ratio: 2.7 : 1 - Good BULLISH [Positioning] Intermediate trend bullish, Downtrend turned sideways, possible bottom. [Timing] Strong bullish 3 day candlestick pattern with Mild 3 day accumulation. [Timing] Good bullish 1 day moneyflow [Timing] breakout watch above 1.37, no resistance in area just above. BEARISH [Positioning] Short term typical rally, rally may start to slow. [Positioning] at resistance
0 · Reply
fmalad
fmalad Jul. 16 at 8:48 PM
$ADCT if FDA is favorable with Lotus 5 we go to 5. If unfavorable we go to .87 on overselling. Either way we win. If bad news on lotus 5 I will triple my holdings under a buck and wait for Lotus 7 to bring give us a home run! Lotus 5 positive news starts a bull run to 10+
1 · Reply
fmalad
fmalad Jul. 14 at 4:26 AM
$ADCT nothing is ever is guaranteed except death and taxes!
0 · Reply
Spartrap
Spartrap Jul. 9 at 11:00 AM
$ADCT company actively groomed for acquisition. Confirmatory trial in the bag. Let's effing go
1 · Reply
Jh900
Jh900 Jul. 7 at 7:52 PM
$ADCT let’s it back up
1 · Reply
TM555
TM555 Jul. 7 at 6:47 PM
$ADCT I’m in
1 · Reply
XQuise
XQuise Jul. 7 at 3:02 PM
$ADCT 📈🤝🧠👈🏻
1 · Reply
Latest News on ADCT
ADC Therapeutics Announces New Employee Inducement Grant

Jul 1, 2026, 4:05 PM EDT - 20 days ago

ADC Therapeutics Announces New Employee Inducement Grant

ADC Therapeutics completes enrollment in Phase 1b Zynlonta trial

2026-06-30T11:20:42.000Z - 22 days ago

ADC Therapeutics completes enrollment in Phase 1b Zynlonta trial

ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial

Jun 30, 2026, 7:15 AM EDT - 22 days ago

ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial

ADC Therapeutics to reduce workforce by 17% globally

2026-06-24T11:35:19.000Z - 4 weeks ago

ADC Therapeutics to reduce workforce by 17% globally

ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities

Jun 24, 2026, 7:30 AM EDT - 4 weeks ago

ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities

ADC

ADC Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

2026-06-08T10:10:32.000Z - 6 weeks ago

ADC Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

ADC Therapeutics price target lowered to $5 from $8 at Stephens

2026-06-04T13:29:09.000Z - 6 weeks ago

ADC Therapeutics price target lowered to $5 from $8 at Stephens

ADC Therapeutics plunges after patient deaths in blood cancer drug trial

Jun 4, 2026, 8:02 AM EDT - 6 weeks ago

ADC Therapeutics plunges after patient deaths in blood cancer drug trial

ADC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

2026-06-04T01:45:07.000Z - 6 weeks ago

ADC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

ADC Therapeutics Transcript: Study result

Jun 3, 2026, 4:30 PM EDT - 6 weeks ago

ADC Therapeutics Transcript: Study result

ADC Therapeutics Slides: Study result

Jun 3, 2026, 4:30 PM EDT - 6 weeks ago

ADC Therapeutics Slides: Study result

ADC Therapeutics Press release: Study result

Jun 3, 2026, 4:30 PM EDT - 6 weeks ago

ADC Therapeutics Press release: Study result

ADC Therapeutics’ Zynlonta combination shows survival efficacy in DLBCL

2026-06-03T20:20:13.000Z - 6 weeks ago

ADC Therapeutics’ Zynlonta combination shows survival efficacy in DLBCL

ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jun 3, 2026, 4:05 PM EDT - 6 weeks ago

ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics Earnings Call Transcript: Q1 2026

May 4, 2026, 8:30 AM EDT - 2 months ago

ADC Therapeutics Earnings Call Transcript: Q1 2026

ADC Therapeutics Earnings release: Q1 2026

May 4, 2026, 8:30 AM EDT - 2 months ago

ADC Therapeutics Earnings release: Q1 2026

ADC Therapeutics Slides: Q1 2026

May 4, 2026, 8:30 AM EDT - 2 months ago

ADC Therapeutics Slides: Q1 2026

ADC Therapeutics Quarterly report: Q1 2026

May 4, 2026, 8:30 AM EDT - 2 months ago

ADC Therapeutics Quarterly report: Q1 2026

ADC Therapeutics reports Q1 EPS (13c) vs. (22c) last year

2026-05-04T11:40:03.000Z - 2 months ago

ADC Therapeutics reports Q1 EPS (13c) vs. (22c) last year

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

May 4, 2026, 7:30 AM EDT - 2 months ago

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

May 1, 2026, 4:05 AM EDT - 2 months ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

Apr 27, 2026, 7:30 AM EDT - 3 months ago

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

ADC Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 3 months ago

ADC Therapeutics Proxy statement: Proxy filing

ADC Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 3 months ago

ADC Therapeutics Proxy statement: Proxy filing

ADC Therapeutics Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 3 months ago

ADC Therapeutics Proxy statement: Proxy filing

ADC Therapeutics Transcript: H.C. Wainwright Home Series

Mar 23, 2026, 7:00 PM EDT - 4 months ago

ADC Therapeutics Transcript: H.C. Wainwright Home Series

ADC Therapeutics price target raised to $8 from $7 at H.C. Wainwright

2026-03-23T10:10:21.000Z - 4 months ago

ADC Therapeutics price target raised to $8 from $7 at H.C. Wainwright

ADC Therapeutics files to sell 9.83M common shares for holders

2026-03-10T21:15:34.000Z - 4 months ago

ADC Therapeutics files to sell 9.83M common shares for holders

ADC Therapeutics Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:30 AM EDT - 4 months ago

ADC Therapeutics Earnings Call Transcript: Q4 2025

ADC Therapeutics Annual report: Q4 2025

Mar 10, 2026, 8:30 AM EDT - 4 months ago

ADC Therapeutics Annual report: Q4 2025

ADC Therapeutics Earnings release: Q4 2025

Mar 10, 2026, 8:30 AM EDT - 4 months ago

ADC Therapeutics Earnings release: Q4 2025

ADC Therapeutics Slides: Q4 2025

Mar 10, 2026, 8:30 AM EDT - 4 months ago

ADC Therapeutics Slides: Q4 2025

ADC Therapeutics Registration statement: Registration Filing

Mar 10, 2026, 8:00 AM EDT - 4 months ago

ADC Therapeutics Registration statement: Registration Filing

ADC Therapeutics reports Q4 adjusted EPS (9c), consensus (27c)

2026-03-10T11:36:29.000Z - 4 months ago

ADC Therapeutics reports Q4 adjusted EPS (9c), consensus (27c)

ADC Therapeutics sees cash runway at least into 2028

2026-03-10T11:35:55.000Z - 4 months ago

ADC Therapeutics sees cash runway at least into 2028

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

Mar 10, 2026, 7:30 AM EDT - 4 months ago

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

ADC Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:50 AM EST - 5 months ago

ADC Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026

Mar 3, 2026, 7:15 AM EST - 5 months ago

ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026

ADC Therapeutics to Participate in March Investor Conferences

Feb 24, 2026, 7:15 AM EST - 5 months ago

ADC Therapeutics to Participate in March Investor Conferences

ADC Therapeutics announces amended HealthCare Royalty financing agreement

2026-02-23T12:21:11.000Z - 5 months ago

ADC Therapeutics announces amended HealthCare Royalty financing agreement

ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement

Feb 23, 2026, 7:15 AM EST - 5 months ago

ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement

ADC Therapeutics participates in a conference call with Cantor

2026-02-03T21:00:27.000Z - 6 months ago

ADC Therapeutics participates in a conference call with Cantor

ADC Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 1:30 PM EST - 6 months ago

ADC Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

ADC Therapeutics sees FY25 net product revenue $73M

2026-01-08T21:17:18.000Z - 6 months ago

ADC Therapeutics sees FY25 net product revenue $73M

ADC Therapeutics sees Q4 net product revenue $22M

2026-01-08T21:10:45.000Z - 6 months ago

ADC Therapeutics sees Q4 net product revenue $22M

ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates

Jan 8, 2026, 4:05 PM EST - 6 months ago

ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates

ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 7:15 AM EST - 6 months ago

ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

ADC Therapeutics Registration statement: Registration Filing

Dec 9, 2025, 7:00 AM EST - 8 months ago

ADC Therapeutics Registration statement: Registration Filing

ADC Therapeutics Transcript: Study Update

Dec 3, 2025, 8:00 AM EST - 8 months ago

ADC Therapeutics Transcript: Study Update

ADC Therapeutics Press release: Study Update

Dec 3, 2025, 8:00 AM EST - 8 months ago

ADC Therapeutics Press release: Study Update

ADC Therapeutics Slides: Study Update

Dec 3, 2025, 8:00 AM EST - 8 months ago

ADC Therapeutics Slides: Study Update

ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma

2025-12-03T12:40:45.000Z - 8 months ago

ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma

ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Dec 3, 2025, 7:30 AM EST - 8 months ago

ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

Dec 2, 2025, 4:05 PM EST - 8 months ago

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

ADC Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 7:30 AM EST - 8 months ago

ADC Therapeutics Transcript: Jefferies London Healthcare Conference 2025

ADC Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 1:30 PM EST - 9 months ago

ADC Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

ADC Therapeutics files to sell 14.7M common shares for holders

2025-11-10T22:30:31.000Z - 9 months ago

ADC Therapeutics files to sell 14.7M common shares for holders

ADC Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 8:30 AM EST - 9 months ago

ADC Therapeutics Earnings Call Transcript: Q3 2025

ADC Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 8:30 AM EST - 9 months ago

ADC Therapeutics Quarterly report: Q3 2025

ADC Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 8:30 AM EST - 9 months ago

ADC Therapeutics Earnings release: Q3 2025

ADC Therapeutics Slides: Q3 2025

Nov 10, 2025, 8:30 AM EST - 9 months ago

ADC Therapeutics Slides: Q3 2025

ADC Therapeutics reports Q3 adjsuted EPS (19c), consensus (36c)

2025-11-10T12:40:45.000Z - 9 months ago

ADC Therapeutics reports Q3 adjsuted EPS (19c), consensus (36c)

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

Nov 10, 2025, 7:30 AM EST - 9 months ago

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

ADC Therapeutics Registration statement: Registration Filing

Nov 10, 2025, 7:00 AM EST - 9 months ago

ADC Therapeutics Registration statement: Registration Filing

ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025

Nov 3, 2025, 7:15 AM EST - 9 months ago

ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025

ADC Therapeutics to Present at November Investor Conferences

Oct 27, 2025, 7:15 AM EDT - 9 months ago

ADC Therapeutics to Present at November Investor Conferences

ADC Therapeutics price target lowered to $7 from $8 at H.C. Wainwright

2025-10-16T10:15:41.000Z - 9 months ago

ADC Therapeutics price target lowered to $7 from $8 at H.C. Wainwright

ADC Therapeutics sees Q3 sales of zynlonta about $15.8M

2025-10-13T11:41:11.000Z - 10 months ago

ADC Therapeutics sees Q3 sales of zynlonta about $15.8M

ADC Therapeutics Announces $60 Million Private Placement

Oct 13, 2025, 7:30 AM EDT - 10 months ago

ADC Therapeutics Announces $60 Million Private Placement

ADC Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:10 AM EDT - 11 months ago

ADC Therapeutics Transcript: Cantor Global Healthcare Conference 2025

ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025

Aug 27, 2025, 7:15 AM EDT - 11 months ago

ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025

ADC Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

ADC Therapeutics Earnings Call Transcript: Q2 2025

ADC Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

ADC Therapeutics Quarterly report: Q2 2025

ADC Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

ADC Therapeutics Earnings release: Q2 2025

ADC Therapeutics Slides: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

ADC Therapeutics Slides: Q2 2025

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 12, 2025, 7:30 AM EDT - 1 year ago

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

Aug 5, 2025, 4:05 PM EDT - 1 year ago

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

Jul 1, 2025, 4:05 PM EDT - 1 year ago

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

ADC Therapeutics Registration statement: Registration Filing

Jun 30, 2025, 8:00 AM EDT - 1 year ago

ADC Therapeutics Registration statement: Registration Filing

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

Jun 16, 2025, 7:15 AM EDT - 1 year ago

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

ADC Therapeutics Transcript: Study Update

Jun 12, 2025, 8:00 AM EDT - 1 year ago

ADC Therapeutics Transcript: Study Update

ADC Therapeutics Press release: Study Update

Jun 12, 2025, 8:00 AM EDT - 1 year ago

ADC Therapeutics Press release: Study Update

ADC Therapeutics Slides: Study Update

Jun 12, 2025, 8:00 AM EDT - 1 year ago

ADC Therapeutics Slides: Study Update

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

Jun 12, 2025, 6:45 AM EDT - 1 year ago

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

Jun 12, 2025, 6:30 AM EDT - 1 year ago

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

ADC Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 21, 2025, 10:30 AM EDT - 1 year ago

ADC Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

ADC Therapeutics to Present at Upcoming Investor Conferences

May 15, 2025, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Present at Upcoming Investor Conferences

ADC Therapeutics Earnings Call Transcript: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

ADC Therapeutics Earnings Call Transcript: Q1 2025

ADC Therapeutics Quarterly report: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

ADC Therapeutics Quarterly report: Q1 2025

ADC Therapeutics Earnings release: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

ADC Therapeutics Earnings release: Q1 2025

ADC Therapeutics Slides: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

ADC Therapeutics Slides: Q1 2025

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

May 14, 2025, 8:00 AM EDT - 1 year ago

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

May 14, 2025, 7:45 AM EDT - 1 year ago

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

May 8, 2025, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

Apr 28, 2025, 7:00 AM EDT - 1 year ago

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

ADC Therapeutics Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

ADC Therapeutics Proxy statement: Proxy Filing

ADC Therapeutics Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

ADC Therapeutics Proxy statement: Proxy Filing

ADC Therapeutics Proxy statement: Proxy Filing

Apr 9, 2025, 8:00 AM EDT - 1 year ago

ADC Therapeutics Proxy statement: Proxy Filing

ADC Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 8, 2025, 8:00 AM EDT - 1 year ago

ADC Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

ADC Therapeutics Earnings Call Transcript: Q4 2024

Mar 27, 2025, 8:30 AM EDT - 1 year ago

ADC Therapeutics Earnings Call Transcript: Q4 2024

ADC Therapeutics Annual report: Q4 2024

Mar 27, 2025, 8:30 AM EDT - 1 year ago

ADC Therapeutics Annual report: Q4 2024

ADC Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 8:30 AM EDT - 1 year ago

ADC Therapeutics Earnings release: Q4 2024

ADC Therapeutics Slides: Q4 2024

Mar 27, 2025, 8:30 AM EDT - 1 year ago

ADC Therapeutics Slides: Q4 2024

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

Mar 27, 2025, 7:30 AM EDT - 1 year ago

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

Mar 25, 2025, 5:30 PM EDT - 1 year ago

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

Mar 20, 2025, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

ADC Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Feb 6, 2025, 2:00 PM EST - 1 year ago

ADC Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:15 AM EST - 1 year ago

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

Dec 30, 2024, 4:30 PM EST - 1 year ago

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

ADC Therapeutics Transcript: Study Update

Dec 11, 2024, 8:30 AM EST - 1 year ago

ADC Therapeutics Transcript: Study Update

ADC Therapeutics Press release: Study Update

Dec 11, 2024, 8:30 AM EST - 1 year ago

ADC Therapeutics Press release: Study Update

ADC Therapeutics Slides: Study Update

Dec 11, 2024, 8:30 AM EST - 1 year ago

ADC Therapeutics Slides: Study Update

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Dec 11, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

Dec 9, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

Dec 6, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

ADC Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 6:00 AM EST - 1 year ago

ADC Therapeutics Transcript: Jefferies London Healthcare Conference 2024

ADC Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 11, 2024, 11:00 AM EST - 1 year ago

ADC Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

ADC Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

ADC Therapeutics Earnings Call Transcript: Q3 2024

ADC Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

ADC Therapeutics Quarterly report: Q3 2024

ADC Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

ADC Therapeutics Earnings release: Q3 2024

ADC Therapeutics Slides: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

ADC Therapeutics Slides: Q3 2024

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

Nov 7, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

Nov 5, 2024, 9:47 AM EST - 1 year ago

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

Oct 31, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

ADC Therapeutics Proxy statement: Proxy Filing

Sep 23, 2024, 8:00 AM EDT - 1 year ago

ADC Therapeutics Proxy statement: Proxy Filing

ADC Therapeutics Proxy statement: Proxy Filing

Sep 23, 2024, 8:00 AM EDT - 1 year ago

ADC Therapeutics Proxy statement: Proxy Filing

ADC Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 11:30 AM EDT - 2 years ago

ADC Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

ADC Therapeutics Proxy statement: Proxy Filing

Sep 13, 2024, 8:00 AM EDT - 2 years ago

ADC Therapeutics Proxy statement: Proxy Filing

ADC Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 7:00 AM EDT - 2 years ago

ADC Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

ADC Therapeutics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 2 years ago

ADC Therapeutics Earnings Call Transcript: Q2 2024

ADC Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 2 years ago

ADC Therapeutics Quarterly report: Q2 2024

ADC Therapeutics Earnings release: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 2 years ago

ADC Therapeutics Earnings release: Q2 2024

ADC Therapeutics Slides: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 2 years ago

ADC Therapeutics Slides: Q2 2024

ADC Therapeutics Registration statement: Registration Filing

Aug 6, 2024, 8:00 AM EDT - 2 years ago

ADC Therapeutics Registration statement: Registration Filing

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Aug 6, 2024, 7:30 AM EDT - 2 years ago

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024

Jul 30, 2024, 7:15 AM EDT - 2 years ago

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

Jul 8, 2024, 2:00 AM EDT - 2 years ago

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

CG

Flying_Trader2
Flying_Trader2 Jul. 20 at 12:08 AM
$ADCT that pullback from 1.45 was disappointing. But we have a couple of important catalysts coming soon so this is either going to 4+ or pennies by year end.
0 · Reply
Spartrap
Spartrap Jul. 19 at 11:47 AM
$ADCT short interest is stable
0 · Reply
XQuise
XQuise Jul. 17 at 2:11 PM
$ADCT 🧠👈🏻🫶🏻
1 · Reply
StockConsultant
StockConsultant Jul. 17 at 1:14 PM
$ADCT Adc Therapeutics stock, watch for an upside gap breakout at https://stockconsultant.com/?ADCT Breakout trade WATCH for possible breakout above 1.37 Target: 1.68, 24.4% Stop: 1.23 Loss: 8.9% P/L ratio: 2.7 : 1 - Good BULLISH [Positioning] Intermediate trend bullish, Downtrend turned sideways, possible bottom. [Timing] Strong bullish 3 day candlestick pattern with Mild 3 day accumulation. [Timing] Good bullish 1 day moneyflow [Timing] breakout watch above 1.37, no resistance in area just above. BEARISH [Positioning] Short term typical rally, rally may start to slow. [Positioning] at resistance
0 · Reply
fmalad
fmalad Jul. 16 at 8:48 PM
$ADCT if FDA is favorable with Lotus 5 we go to 5. If unfavorable we go to .87 on overselling. Either way we win. If bad news on lotus 5 I will triple my holdings under a buck and wait for Lotus 7 to bring give us a home run! Lotus 5 positive news starts a bull run to 10+
1 · Reply
fmalad
fmalad Jul. 14 at 4:26 AM
$ADCT nothing is ever is guaranteed except death and taxes!
0 · Reply
Spartrap
Spartrap Jul. 9 at 11:00 AM
$ADCT company actively groomed for acquisition. Confirmatory trial in the bag. Let's effing go
1 · Reply
Jh900
Jh900 Jul. 7 at 7:52 PM
$ADCT let’s it back up
1 · Reply
TM555
TM555 Jul. 7 at 6:47 PM
$ADCT I’m in
1 · Reply
XQuise
XQuise Jul. 7 at 3:02 PM
$ADCT 📈🤝🧠👈🏻
1 · Reply
Bdorris2
Bdorris2 Jul. 6 at 10:59 PM
$ADCT https://x.com/fridayfurnace/status/2073829266794672146?s=12&t=xfwFRkUdYzB-jK7V0E5rBg
1 · Reply
MikeCaymanTrades
MikeCaymanTrades Jul. 5 at 12:28 AM
$ADCT Signal Update Today's recommendation from our system is to STAY LONG. The previous BUY signal was issued on 06/30/2026, 2 days ago, when the stock price was 1.0700. Since then, ADCT has risen by +11.21% Open gap above. Needs to break 1.50
0 · Reply
fmalad
fmalad Jul. 3 at 5:29 PM
$ADCT 5x before year end not. Hopefully Lotus 7 days will be released in January which moves us to 5-8. Once sales start coming in 10-15! If August 4 gives us approval on lotus 5 then adjust figures!
2 · Reply
tom1_tom1
tom1_tom1 Jul. 3 at 1:25 PM
$ADCT go back to $3
1 · Reply
focafoca99
focafoca99 Jul. 2 at 9:44 PM
$ADCT locks in CEO and top execs with retention awards, including cash and RSUs vesting through 2027.
0 · Reply
jazzv
jazzv Jul. 2 at 12:59 AM
$ADCT eye on this.
0 · Reply
CrackheadApparel
CrackheadApparel Jul. 1 at 1:21 PM
$ADCT Chatgpt assessment of Lotis 5 on the positive side. 1. The Phase 3 trial succeeded Primary endpoint met Statistically significant improvement in progression-free survival (PFS) A 27% reduction in the risk of progression or death is a respectable Phase 3 result. For a company with an accelerated approval product, completing a positive confirmatory study substantially reduces regulatory risk. 2. Higher complete response rates These numbers are impressive. Endpoint ZYNLONTA + Rituximab R-GemOx ORR 58.1% 45.2% CR 39.5% 26.7% Duration of CR 16.8 months 12.3 months Nearly 40% complete responses is attractive in relapsed/refractory DLBCL. The 24-month durability is particularly encouraging: That suggests patients who achieve remission may remain disease-free substantially longer. 3. Overall survival was not worse 4. Confirmatory trial supports full approval 5. Better efficacy than R-GemOx higher ORR & CR longer responses better PFS
1 · Reply
Spartrap
Spartrap Jun. 30 at 11:55 AM
$ADCT this is going to x5 before EOY https://ir.adctherapeutics.com/2026-06-30-ADC-Therapeutics-Announces-Completion-of-Enrollment-in-LOTIS-7-Phase-1b-ZYNLONTA-R-Combination-Trial
3 · Reply
CrackheadApparel
CrackheadApparel Jun. 29 at 1:22 PM
$ADCT this is the most undervalued stock. I am long on this.
0 · Reply
focafoca99
focafoca99 Jun. 24 at 1:16 PM
$ADCT announced a 17% global workforce cut, targeting $10 million in annual savings with $3 million in one‑time severance costs.
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 24 at 1:13 PM
ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details $ADCT https://stocktwits.com/news/equity/markets/adc-therapeutics-in-focus-layoffs-reorganization-zynlonta-franchise/cZKya9bR7fg
0 · Reply
Spartrap
Spartrap Jun. 24 at 12:58 PM
$ADCT symbolic reorganization showing commitment to disciplined spendings without sacrificing much, if any, operational capabilities. Shaving off 5% of the forward burn rate maybe. Balance sheet good till 2028+
0 · Reply